| 4.06 0.46 (12.78%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.38 | 1-year : | 8.35 |
| Resists | First : | 5.46 | Second : | 7.15 |
| Pivot price | 3.91 |
|||
| Supports | First : | 2.75 | Second : | 2.28 |
| MAs | MA(5) : | 3.91  |
MA(20) : | 3.84 |
| MA(100) : | 6.55 |
MA(250) : | 9.81 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 20.2 |
D(3) : | 21.3 |
| RSI | RSI(14): 47.6 |
|||
| 52-week | High : | 17 | Low : | 2.75 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TOVX ] has closed below upper band by 44.6%. Bollinger Bands are 14.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.19 - 4.22 | 4.22 - 4.25 |
| Low: | 3.71 - 3.74 | 3.74 - 3.76 |
| Close: | 4.02 - 4.07 | 4.07 - 4.1 |
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.
Wed, 04 Sep 2024
Theriva Biologics (TOVX) Is Making Noise With a Promising Pipeline - TipRanks
Fri, 30 Aug 2024
What's Going On With Theriva Biologics Stock? - Benzinga
Tue, 20 Aug 2024
Peering Into Theriva Biologics's Recent Short Interest - Benzinga
Mon, 19 Aug 2024
What's Going On With Theriva Biologics (TOVX) Stock? - Benzinga
Fri, 16 Aug 2024
Theriva Biologics announces reverse stock split - Investing.com
Fri, 16 Aug 2024
Theriva Biologics Announces Reverse Stock Split | TOVX Stock News - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 17 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 1.9 (%) |
| Held by Institutions | 6.2 (%) |
| Shares Short | 385 (K) |
| Shares Short P.Month | 413 (K) |
| EPS | -1.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.41 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -21.2 % |
| Return on Equity (ttm) | -37.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -18 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -3.25 |
| PEG Ratio | 0 |
| Price to Book value | 1.68 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.89 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|